Items tagged with Treatment
Rigid treatments can cause disease to spread (post)
Rigid treatments of tuberculosis could lead to the emergence of more drug-resistant tuberculosis instead of less, new study shows.
Call for expressions of interest: Systematic reviews on dose optimization of the first-line TB medicines (post)
22 July 2020, Geneva | The World Health Organization (WHO) Global Tuberculosis Programme has initiated a process for the collection and assessment of evidence on whether the dosing of rifampicin, isoniazid, ethambutol and pyrazinamide requires further optimization to safely improve treatment success and reduce unfavourable treatment outcomes in TB patients on first-line treatment regimens.
Mylan secures DCGI approval in India for pretomanid, a treatment for highly drug-resistant forms of TB (post)
Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years
Approval comes as a result of Mylan’s global collaboration with non-profit drug development partner TB Alliance
TB Alliance announces European Commission authorisation of new treatment for highly drug-resistant TB (post)
Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB.
Target product profiles for TB preventive treatment (post)
The World Health Organization released target product profiles to drive the rapid development of novel TB preventive treatment. The target product profiles characterise the most important product attributes to be considered for developing the best suited TB prevention treatments in future.
COVID-19: The fascinating science of what happens in the lungs (post)
People with COVID-19 and people with tuberculosis (TB) can experience similar symptoms such as coughing and breathing difficulties as both diseases affect the lungs. Exactly how these diseases affect the lungs, however, differs.
TB Alliance with the support of the Republic of Korea announce initiative to broaden adoption and scale up of new treatments for drug-resistant TB (post)
LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder about 1 in 5 TB case.
India: Two clinical trials initiated to assess efficacy of short treatments for MDR-TB (post)
Two major clinical trials have been initiated with an aim to generate clinical evidence on the safety and efficacy of novel, short and all-oral regimens for strains of tuberculosis (TB) that are most difficult to treat.
The Medication Adherence Expertise Center and Pill Connect’s smart adherence system help patients with TB take their medication regularly (post)
A pilot trial at The Medication Adherence Expertise Center of the University Medical Center Groningen in the Netherlands is determining whether Pill Connect’s smart bottle system can support patients with tuberculosis (TB) with their medication adherence.
Funded by Stop TB Partnership TB REACH: People with TB in Ukraine are the first to receive groundbreaking new BPal drug regimen (post)
23 November 2020, KIEV, UKRAINE / THE HAGUE, NETHERLANDS: Ukraine is the first country in the world, under programmatic conditions, to provide tuberculosis (TB) patients with the groundbreaking new BPaL treatment. This three-drug treatment is meant for patients with extensively drug-resistant TB (XDR-TB) and is expected to have a higher success rate than previous treatments, doing away with painful daily injections. This deadly infectious disease currently ranks as the third cause of death in Ukraine among communicable, maternal, neonatal and nutritional diseases.
Page 54 of 106 · Total posts: 0
←First 53 54 55 Last→